questionnaires
OtherAll patients will complete a number of questionnaires at different time points.
- SF-12, WHOQoL-Bref, EQ-5D-5L, iPCQ, iMCQ
- 1 week, 1 month, 3, 6 and 12 months after treatment
NCT Number: NCT03099798
OBJECTIVE:
To determine the quality of life (QOL) and clinical outcome after conservative therapy, embolization (proximal versus distal) or surgery in patients with traumatic splenic injury. Secondary aims: (I) to examine therapy-related complications, (II) to establish the necessity of additional therapies, (III) the assessment of splenic function related to splenic morphology (MR imaging) after embolization and (IV) to find the prognostic factors for failure of non-operative management (NOM) in patients with splenic injuries. Finally, with the acquired data from this study a patient-oriented protocol will be provided for the management of traumatic splenic injury.
HYPOTHESIS:
The investigators expect that NOM is superior to surgery with regard to QOL, clinical outcome and splenic function. Embolization will need more additional therapies. Splenic morphology is related to splenic immune function. Expected prognostic factors are age above 40, ISS >25 and a splenic injury grade of 3 or higher.
STUDY DESIGN:
A combination of a retrospective and a prospective multicentre cohort study. This protocol involves the prospective part of the study.
STUDY POPULATION/DATASET:
Patients who enter the participating hospitals between March 2017 and December 2018 with splenic injury will be asked to participate. The follow-up period will be one year with regard to QOL, clinical symptoms and imaging.
INTERVENTION:
All patients will complete a number of questionnaires at different time points. The patients who were treated with splenic artery embolization (SAE) will undergo an MRI one month and one year after treatment.
OUTCOME MEASURES:
Primary outcome is QOL. Secondary outcomes are clinical symptoms and imaging.
SAMPLE SIZE:
Approximately 100 patients will be included per year during the inclusion phase.
DATA ANALYSIS:
With regard to the prospective data linear modelling will be performed.
COLLABORATION/CONNECTION:
Tilburg University, Erasmus Medical Center Rotterdam, Maasstad Hospital Rotterdam, Albert Schweitzer Hospital Dordrecht, Amphia hospital Breda, Leiden University Medical Center, VU University Medical Center Amsterdam, Medical Spectrum Twente, Radboud University Nijmegen, Isala Zwolle.
TIME SCHEDULE:
Year 1: literature search and conducting the retrospective study and analyses. Years 1-3: inclusion prospective study and follow-up of patients. Year 4: finishing follow-up data collection and analysing.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Radboud University Medical Center, Nijmegen, Gelderland, Netherlands
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Exclusion for MRI only:
All patients will complete a number of questionnaires at different time points.
Patients who were treated with splenic artery embolization will also undergo an MRI one month and one year after treatment.
Time frame: One week after treatment
WHOQoL-Bref questionnaire, SF-12 and EQ-5D-5L questionnaires
Time frame: One month after treatment
WHOQoL-Bref questionnaire
Time frame: Three months after treatment
WHOQoL-Bref questionnaire
Time frame: Six months after treatment
WHOQoL-Bref questionnaire
Time frame: One year after treatment
WHOQoL-Bref questionnaire
Time frame: One week, 1 month and 3, 6 and 12 months after treatment
SF-12 questionnaire
Time frame: One week, 1 month and 3, 6 and 12 months after treatment
EQ-5D-5L questionnaire
Time frame: One year follow-up
Data obtained from the patient records (e.g. complications, need for re-intervention, hospital stay, return to daily activities)
Time frame: One year follow-up
The overall cost-effectiveness will be assessed with the iPCQ and iMCQ questionnaires, completed at different time points
Time frame: One month after embolization
Splenic morphological characteristics (e.g. volume, necrosis, splenosis, calcifications or chronic infarction morphology)
Time frame: One year after embolization
Splenic morphological characteristics (e.g.volume, necrosis, splenosis, calcifications or chronic infarction morphology)
Time frame: One year follow-up
Difference between proximal versus distal embolization
Time frame: One year follow-up
A recent study suggests that there are prognostic factors for failure of NOM in the treatment of adults with (blunt) splenic injury. Strong evidence exists for: age of 40 years or above, Injury Severity Score (ISS) of 25 or greater and American Association for the Surgery of Trauma (AAST) splenic injury grade of 3 or greater.
Elisabeth-TweeSteden Ziekenhuis
Other
Traumatic Splenic Injury and Management (SPLENIQ Study) Quality of Life and Clinical Outcomes of Treatment for Splenic Injury After Trauma
Acronym: SPLENIQ
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04092504
Fragility, Geriatric Assessment
Gothenburg, Sweden
View Trial DetailsNCT06027658
Anxiety Disorders, Attachment Disorder
Paris, France
View Trial DetailsNCT06370260
Biopsy Wound, Dental Deposits
Athens, Attica, Greece
View Trial DetailsNCT02655354
Alcohol-Related Disorders, Behavior
Scottsdale, Arizona, United States
View Trial Details